Jefferies Raises PT on BioMarin Pharmaceuticals to $38

Symbols: BMRN
Share

Jefferies & Company has raised the price target on BioMarin Pharmaceuticals (NASDAQ: BMRN) from $35 to $38 and maintains its Buy rating.


 
 
< Previous
Jefferies Raises PT on American Electric Power to $39
Next >
Bank of America Raises PO On Cymer to $52, Maintains Buy
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust